Search

Myeloproliferative Neoplasms (MPN)

The aims of the SWG are furthering collaboration and sharing knowledge between centers involved in the management of MPN, a focus to develop centers and clinicians who would be willing to host visiting staff for sabbaticals or learning experiences was…

Read more

EHA Diagnosis - Coming in 2024

EHA Diagnosis is a new digital tool that EHA has created exclusively for our members.

Read more

Bleeding and Thrombosis

The objectives of the SWG on ‘Bleeding and Thrombosis’ are:

To promote education in the field of blood coagulation, including mechanisms, prevention, and treatment of bleeding and thrombotic disorders.

Read more

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Support for Research

Research in hematology is critical to improving our understanding of diseases, clinical practice, and overall patient care. Support for research in hematology is a priority for EHA, including for our European Affairs team.

Read more